The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.

BET inhibitor Drug combinations Neuroblastoma RKI-1447 ROCK inhibitor

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
20 Sep 2024
Historique:
received: 08 03 2024
revised: 09 09 2024
accepted: 12 09 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 22 9 2024
Statut: aheadofprint

Résumé

High-risk neuroblastoma has a poor prognosis despite intensive treatment, highlighting the need for new therapeutic strategies. Genetic alterations in activators and inactivators of Rho GTPase have been identified in neuroblastoma suggested to activate Rho/Rho-kinase (ROCK) signaling. ROCK has also been implicated in therapy resistance. Therefore, we have explored the efficacy of the dual ROCK inhibitor RKI-1447 in neuroblastoma, emphasizing combination strategies. Treatment with RKI-1447 resulted in decreased growth, increased cell death, and inhibition of N-MYC in vitro and in vivo. A combination screen revealed enhanced effects between RKI-1447 and BET inhibitors. Synergistic effects from RKI-1447 and the BET inhibitor, ABBV-075, were confirmed in various neuroblastoma models, including zebrafish. Interestingly, ABBV-075 increased phosphorylation of both myosin light chain 2 and cofilin, downstream effectors of ROCK, increases that were blocked by adding RKI-1447. The combination treatment also augmented an inhibitory effect on C-MYC and, less pronounced, N-MYC protein expression. BET inhibitors have shown preclinical efficacy against neuroblastoma, but acquired resistance has limited their therapeutic benefit. We reveal that the combination of ROCK and BET inhibitors offers a promising treatment approach that can potentially mitigate resistance to BET inhibitors and reduce toxicity.

Identifiants

pubmed: 39307412
pii: S0304-3835(24)00656-6
doi: 10.1016/j.canlet.2024.217261
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217261

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The author is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for [Journal name] and was not involved in the editorial review or the decision to publish this article.

Auteurs

Adena Pepich (A)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet. Electronic address: malin.wickstrom@ki.se.

Conny Tümmler (C)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Sara Abu Ajamieh (S)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Diana Treis (D)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Ammelie Svea Boje (AS)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Christian Albrechts University and University Hospital Schleswig-Holstein, Kiel, Germany.

Quinty Vellema (Q)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Ioanna Tsea (I)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Emma Åkerlund (E)

Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

Brinton Seashore-Ludlow (B)

Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

Shahrzad Shirazi Fard (S)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Per Kogner (P)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

John Inge Johnsen (JI)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet.

Malin Wickström (M)

Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet. Electronic address: adena.pepich@ki.se.

Classifications MeSH